retatrutide ly3437943 clinical trial results (LY3437943): Mechanism of Action and Research Overview LY3437943 – GLP-3 RT –

You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)

Holthusen D, Brandt AA, Reichert JM, Horn R (2018a) Soil porosity, permeability and static and dynamic strength parameters under native forest/grassland compared to no-tillage cropping

10.1016/j.neuroscience.2003.12.029 Neuroscience 18 DoK

This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Second Hospital of Nanjing (2024-LS-ky044